:: Library Catalog

Cover Image

Saved in:

Bibliographic Details
Main Author:	Iskandar Idris
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Diabetes, Obesity and Metabolism Now
Online Access:	https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1002/doi2.94
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Precision medicine approach to detect obese people who are at high risk of developing diabetes
by: Iskandar Idris
Published: (2024)

Appropriate timing of exercise for adults with obesity including those with type 2 diabetes
by: Iskandar Idris
Published: (2024)

Tirzepatide shown to improve clinical outcomes for patients with heart failure with preserved ejection fraction (HFpEF) and obesity
by: Iskandar Idris
Published: (2024)

Can diet and exercise intervention prevent type 2 diabetes in individuals with a high genetic risk?
by: Iskandar Idris
Published: (2024)

Increasing excess to weight loss injection shown to save thousands of lives a year
by: Iskandar Idris
Published: (2024)

Increased expression of the protein Kallistatin after weight loss induces beneficial metabolic effects: A potential new therapeutic target?
by: Iskandar Idris
Published: (2024)

Real world data showed that the dual GLP gip agonist, Tirzepatide is associated with lower mortality, cardiovascular events and adverse kidney events compared with GLP‐1 analogue
by: Iskandar Idris
Published: (2024)

Hybrid closed‐loop therapy significantly improved maternal glucose control during pregnancy complicated by type 1 diabetes
by: Iskandar Idris
Published: (2024)

The glucagon like peptide‐1 linked to nonarteritic anterior ischemic optic neuropathy
by: Iskandar Idris
Published: (2024)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
by: Iskandar Idris
Published: (2024)

Tirzepatide shown to be effective at reducing sleep disturbances in patients with obstructive sleep apnoea
by: Iskandar Idris
Published: (2024)

Extension study from DIRECT showed ongoing remission rate from type 2 diabetes in some patient following very low calorie diet at 5 years
by: Iskandar Idris
Published: (2024)

Glucagon like peptide‐1 (GLP‐1) therapy is associated with reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes with chronic liver disease
by: Iskandar Idris
Published: (2024)

The US Food and Drug administration has approved resmetirom as the first drug to treat metabolic dysfunction‐associated steatohepatitis (MASH)
by: Iskandar Idris
Published: (2024)

Potential new therapies to preserve lean muscle mass loss when used in combination with glucagon‐like peptide 1 (GLP‐1) receptor agonist being studied
by: Iskandar Idris
Published: (2024)

Epigenetic changes shown to cause type 2 diabetes
by: Iskandar Idris
Published: (2024)

Real world study provided reassurance of the safety of GLP‐1 therapy on mental health and suicide risk
by: Iskandar Idris
Published: (2024)

Fenofibrate shown to reduce progression of diabetic retinopathy
by: Iskandar Idris
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

The latest evidence and guidance in lifestyle and surgical interventions to achieve weight loss in people with overweight or obesity
by: Iskandar Idris, et al.
Published: (2025)

Adherence to liraglutide among individuals with overweight and obesity: Patient characteristics and clinical measures
by: Amit Guy, et al.
Published: (2024)

The real‐life experiences of people living with overweight and obesity: A psychosocial perspective
by: Stuart W. Flint, et al.
Published: (2025)

Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight
by: Michelle Look, et al.
Published: (2025)

Association between patient‐reported eating behaviours and weight change: Secondary analyses of a randomized, double‐blind trial comparing retatrutide and placebo in people with obesity or overweight
by: Chisom Kanu, et al.
Published: (2025)

Correction to “Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight”
Published: (2025)

Association of overweight/obesity and overweight/obesity‐related metabolic dysfunction‐associated steatotic liver disease in young adults with coronary artery calcification later in life
by: Jia‐Jie Wang, et al.
Published: (2024)

Changes in thyroid hormones predict weight regain in patients with obesity who undergo metabolic surgery
by: Yi Tang, et al.
Published: (2024)

Effects of light‐intensity physical activity on cardiometabolic parameters in young adults with overweight and obesity: The SED ‐ ACT randomized controlled crossover trial
by: Sascha W. Hoffmann, et al.
Published: (2024)

Impact of eligibility for diabetes remission on response to intensive lifestyle intervention in overweight and obese people with type 2 diabetes: The Look AHEAD trial
by: Joanna Y. Gong, et al.
Published: (2025)

Exploring population and sex‐specific disease trajectories for multimorbidities among individuals with overweight or obesity: A retrospective cohort study in UK biobank
by: Qianhui Lu, et al.
Published: (2025)

Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT ‐1 to ‐4 trials
by: Domenica M. Rubino, et al.
Published: (2025)

The impact of overweight and obesity on health outcomes in the United States from 1990 to 2021
by: Omar Al Ta'ani, et al.
Published: (2024)

Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER )
by: Lauren Wilson, et al.
Published: (2026)